Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Meta-analytic Evidence for the Plurality of Mechanisms in Transdiagnostic Structural MRI Studies of Hallucination Status.

Rollins CPE, Garrison JR, Simons JS, Rowe JB, O'Callaghan C, Murray GK, Suckling J.

EClinicalMedicine. 2019 Feb 21;8:57-71. doi: 10.1016/j.eclinm.2019.01.012. eCollection 2019 Feb.

2.

Education modulates brain maintenance in presymptomatic frontotemporal dementia.

Gazzina S, Grassi M, Premi E, Cosseddu M, Alberici A, Archetti S, Gasparotti R, Van Swieten J, Galimberti D, Sanchez-Valle R, Laforce RJ, Moreno F, Synofzik M, Graff C, Masellis M, Tartaglia MC, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler CR, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni G, Sorbi S, Padovani A, Rohrer JD, Borroni B; Genetic FTD Initiative, GENFI.

J Neurol Neurosurg Psychiatry. 2019 Jun 10. pii: jnnp-2019-320439. doi: 10.1136/jnnp-2019-320439. [Epub ahead of print]

PMID:
31182509
3.

Inflammation and Cerebral Small Vessel Disease: A Systematic Review.

Low A, Mak E, Rowe JB, Markus HS, O'Brien JT.

Ageing Res Rev. 2019 Jun 7:100916. doi: 10.1016/j.arr.2019.100916. [Epub ahead of print] Review.

PMID:
31181331
4.

The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration.

Passamonti L, Lansdall CJ, Rowe JB.

Curr Opin Behav Sci. 2018 Aug;22:14-20. doi: 10.1016/j.cobeha.2017.12.015.

5.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

6.

ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-β copathology.

Koriath C, Lashley T, Taylor W, Druyeh R, Dimitriadis A, Denning N, Williams J, Warren JD, Fox NC, Schott JM, Rowe JB, Collinge J, Rohrer JD, Mead S.

Alzheimers Dement (Amst). 2019 Mar 19;11:277-280. doi: 10.1016/j.dadm.2019.01.010. eCollection 2019 Dec.

7.

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease.

Koychev I, Lawson J, Chessell T, Mackay C, Gunn R, Sahakian B, Rowe JB, Thomas AJ, Rochester L, Chan D, Tom B, Malhotra P, Ballard C, Chessell I, Ritchie CW, Raymont V, Leroi I, Lengyel I, Murray M, Thomas DL, Gallacher J, Lovestone S.

BMJ Open. 2019 Mar 23;9(3):e024498. doi: 10.1136/bmjopen-2018-024498.

8.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Mar 18. doi: 10.1002/mds.27666. [Epub ahead of print]

PMID:
30884545
9.

Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.

Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, Lees AJ, Foltynie T, Houlden H, Church A, Hu MT, Rowe JB, Zetterberg H, Morris HR.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):768-773. doi: 10.1136/jnnp-2018-320151. Epub 2019 Mar 13.

10.

Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study.

Mutsaerts HJMM, Mirza SS, Petr J, Thomas DL, Cash DM, Bocchetta M, de Vita E, Metcalfe AWS, Shirzadi Z, Robertson AD, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Keren R, Rogaeva E, van Swieten J, Laforce R, Tagliavini F, Borroni B, Galimberti D, Rowe JB, Graff C, Frisoni GB, Finger E, Sorbi S, de Mendonça A, Rohrer JD, MacIntosh BJ, Masellis M; GENetic Frontotemporal dementia Initiative (GENFI) .

Brain. 2019 Apr 1;142(4):1108-1120. doi: 10.1093/brain/awz039. Erratum in: Brain. 2019 Jun 1;142(6):e28.

11.

In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FI, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2019 Jan 2;6(2):373-378. doi: 10.1002/acn3.683. eCollection 2019 Feb.

12.

Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration.

Lansdall CJ, Coyle-Gilchrist ITS, Vázquez Rodríguez P, Wilcox A, Wehmann E, Robbins TW, Rowe JB.

Neurology. 2019 Apr 2;92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249. Epub 2019 Mar 6.

13.

Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia.

Rittman T, Borchert R, Jones S, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, Mendonça A, Sorbi S, Rohrer JD, Rowe JB; Genetic Frontotemporal Dementia Initiative (GENFI).

Neurobiol Aging. 2019 May;77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009. Epub 2019 Jan 4.

14.

Disease-informed brain mapping teaches important lessons about the human brain.

Dagher A, Lehéricy S, Rowe JB, Siebner HR.

Neuroimage. 2019 Apr 15;190:1-3. doi: 10.1016/j.neuroimage.2019.02.040. Epub 2019 Feb 21. No abstract available.

PMID:
30798013
15.

Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort.

Cury C, Durrleman S, Cash DM, Lorenzi M, Nicholas JM, Bocchetta M, van Swieten JC, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Ourselin S, Rohrer JD, Modat M; Genetic FTD Initiative, GENFI.

Neuroimage. 2019 Mar;188:282-290. doi: 10.1016/j.neuroimage.2018.11.063. Epub 2018 Dec 6.

16.

Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.

Swarup V, Hinz FI, Rexach JE, Noguchi KI, Toyoshiba H, Oda A, Hirai K, Sarkar A, Seyfried NT, Cheng C, Haggarty SJ; International Frontotemporal Dementia Genomics Consortium, Grossman M, Van Deerlin VM, Trojanowski JQ, Lah JJ, Levey AI, Kondou S, Geschwind DH.

Nat Med. 2019 Jan;25(1):152-164. doi: 10.1038/s41591-018-0223-3. Epub 2018 Dec 3.

PMID:
30510257
17.

Publisher Correction: Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose.

Wolpe N, Zhang J, Nombela C, Ingram JN, Wolpert DM; Cam-CAN, Rowe JB.

Sci Rep. 2018 Nov 22;8(1):17429. doi: 10.1038/s41598-018-35439-8.

18.

The role of dopamine in the brain - lessons learned from Parkinson's disease.

Meder D, Herz DM, Rowe JB, Lehéricy S, Siebner HR.

Neuroimage. 2019 Apr 15;190:79-93. doi: 10.1016/j.neuroimage.2018.11.021. Epub 2018 Nov 20. Review.

19.

Directly Measuring the Rate of Slacking as Stroke Survivors produced Isometric Forces during a Tracking Task.

Smith BW, Rowe JB, Reinkensmeyer DJ.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:2519-2522. doi: 10.1109/EMBC.2018.8512740.

PMID:
30440920
20.

In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease.

Mak E, Bethlehem RAI, Romero-Garcia R, Cervenka S, Rittman T, Gabel S, Surendranathan A, Bevan-Jones RW, Passamonti L, Vázquez Rodríguez P, Su L, Arnold R, Williams GB, Hong YT, Fryer TD, Aigbirhio FI, Rowe JB, O'Brien JT.

Alzheimers Dement (Amst). 2018 Sep 17;10:678-687. doi: 10.1016/j.dadm.2018.08.005. eCollection 2018.

21.

Strong and specific associations between cardiovascular risk factors and white matter micro- and macrostructure in healthy aging.

Fuhrmann D, Nesbitt D, Shafto M, Rowe JB, Price D, Gadie A; Cam-CAN, Kievit RA.

Neurobiol Aging. 2019 Feb;74:46-55. doi: 10.1016/j.neurobiolaging.2018.10.005. Epub 2018 Oct 12.

22.

Early microglial activation and peripheral inflammation in dementia with Lewy bodies.

Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, Vázquez Rodríguez P, Bevan-Jones WR, Brain SAE, Fryer TD, Aigbirhio FI, Rowe JB, O'Brien JT.

Brain. 2018 Dec 1;141(12):3415-3427. doi: 10.1093/brain/awy265.

23.

Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose.

Wolpe N, Zhang J, Nombela C, Ingram JN, Wolpert DM; Cam-CAN, Rowe JB.

Sci Rep. 2018 Oct 23;8(1):15643. doi: 10.1038/s41598-018-33678-3. Erratum in: Sci Rep. 2018 Nov 22;8(1):17429.

24.

[18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion.

Bevan-Jones RW, Cope TE, Jones SP, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FA, Patterson K, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2018 Sep 14;5(10):1292-1296. doi: 10.1002/acn3.631. eCollection 2018 Oct.

25.

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.

Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Warren JD, Crutch S, Fox NC, Ourselin S, Schott JM, Rohrer JD, Alexander DC; Genetic FTD Initiative (GENFI); Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2018 Oct 15;9(1):4273. doi: 10.1038/s41467-018-05892-0.

26.

Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans.

Skandali N, Rowe JB, Voon V, Deakin JB, Cardinal RN, Cormack F, Passamonti L, Bevan-Jones WR, Regenthal R, Chamberlain SR, Robbins TW, Sahakian BJ.

Neuropsychopharmacology. 2018 Dec;43(13):2645-2651. doi: 10.1038/s41386-018-0229-z. Epub 2018 Sep 26.

27.

Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.

Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, Quinn L, Mok TH, Dimitriadis A, Norsworthy P, Bass N, Carter J, Walker Z, Kipps C, Coulthard E, Polke JM, Bernal-Quiros M, Denning N, Thomas R, Raybould R, Williams J, Mummery CJ, Wild EJ, Houlden H, Tabrizi SJ, Rossor MN, Hummerich H, Warren JD, Rowe JB, Rohrer JD, Schott JM, Fox NC, Collinge J, Mead S.

Mol Psychiatry. 2018 Oct 2. doi: 10.1038/s41380-018-0224-0. [Epub ahead of print]

28.

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers.

Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, Sato C, Grinberg M, Liang Y, Xi Z, Dupont K, McGoldrick P, Weichert A, McKeever PM, Schneider R, McCorkindale MD, Manzoni C, Rademakers R, Graff-Radford NR, Dickson DW, Parisi JE, Boeve BF, Petersen RC, Miller BL, Seeley WW, van Swieten JC, van Rooij J, Pijnenburg Y, van der Zee J, Van Broeckhoven C, Le Ber I, Van Deerlin V, Suh E, Rohrer JD, Mead S, Graff C, Öijerstedt L, Pickering-Brown S, Rollinson S, Rossi G, Tagliavini F, Brooks WS, Dobson-Stone C, Halliday GM, Hodges JR, Piguet O, Binetti G, Benussi L, Ghidoni R, Nacmias B, Sorbi S, Bruni AC, Galimberti D, Scarpini E, Rainero I, Rubino E, Clarimon J, Lleó A, Ruiz A, Hernández I, Pastor P, Diez-Fairen M, Borroni B, Pasquier F, Deramecourt V, Lebouvier T, Perneczky R, Diehl-Schmid J, Grafman J, Huey ED, Mayeux R, Nalls MA, Hernandez D, Singleton A, Momeni P, Zeng Z, Hardy J, Robertson J, Zinman L, Rogaeva E; International FTD-Genomics Consortium (IFGC) .

Brain. 2018 Oct 1;141(10):2895-2907. doi: 10.1093/brain/awy238.

29.

Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration.

Hughes LE, Rittman T, Robbins TW, Rowe JB.

Brain. 2018 Oct 1;141(10):e74. doi: 10.1093/brain/awy235. No abstract available.

PMID:
30212860
30.

Aβ42/Aβ40 and Aβ42/Aβ38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study.

Koychev I, Galna B, Zetterberg H, Lawson J, Zamboni G, Ridha BH, Rowe JB, Thomas A, Howard R, Malhotra P, Ritchie C, Lovestone S, Rochester L.

J Alzheimers Dis. 2018;65(4):1377-1383. doi: 10.3233/JAD-180622.

31.

Submicron Aggregation of Chemically Denatured Monoclonal Antibody.

Rowe JB, Flynn RP, Wooten HR, Noufer HA, Cancel RA, Zhang J, Subramony JA, Pechenov S, Wang Y.

Mol Pharm. 2018 Oct 1;15(10):4710-4721. doi: 10.1021/acs.molpharmaceut.8b00690. Epub 2018 Sep 5.

PMID:
30142275
32.

Real-time slacking as a default mode of grip force control: implications for force minimization and personal grip force variation.

Smith BW, Rowe JB, Reinkensmeyer DJ.

J Neurophysiol. 2018 Oct 1;120(4):2107-2120. doi: 10.1152/jn.00700.2017. Epub 2018 Aug 8.

PMID:
30089024
33.

Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype.

Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, Henson RN, Rowe JB.

Brain. 2018 Aug 1;141(8):2500-2510. doi: 10.1093/brain/awy180.

34.

Activity and Connectivity Differences Underlying Inhibitory Control Across the Adult Life Span.

Tsvetanov KA, Ye Z, Hughes L, Samu D, Treder MS, Wolpe N, Tyler LK, Rowe JB; Cambridge Centre for Ageing and Neuroscience.

J Neurosci. 2018 Sep 5;38(36):7887-7900. doi: 10.1523/JNEUROSCI.2919-17.2018. Epub 2018 Jul 26.

35.

Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort.

Sellami L, Bocchetta M, Masellis M, Cash DM, Dick KM, van Swieten J, Borroni B, Galimberti D, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni G, Finger E, de Mendonça A, Sorbi S, Warren JD, Rohrer JD, Laforce R; Genetic FTD Initiative, GENFI.

J Alzheimers Dis. 2018;65(1):147-163. doi: 10.3233/JAD-180053.

36.

Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia.

Hughes LE, Rittman T, Robbins TW, Rowe JB.

Brain. 2018 Aug 1;141(8):2486-2499. doi: 10.1093/brain/awy176.

37.

Exploring patterns of response across the lifespan: the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study.

Green E, Bennett H, Brayne C; Cam-CAN, Matthews FE.

BMC Public Health. 2018 Jun 19;18(1):760. doi: 10.1186/s12889-018-5663-7.

38.

Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales.

Fumagalli GG, Basilico P, Arighi A, Bocchetta M, Dick KM, Cash DM, Harding S, Mercurio M, Fenoglio C, Pietroboni AM, Ghezzi L, van Swieten J, Borroni B, de Mendonça A, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, Sorbi S, Scarpini E, Rohrer JD, Galimberti D; Genetic FTD Initiative (GENFI).

Alzheimers Res Ther. 2018 May 24;10(1):46. doi: 10.1186/s13195-018-0376-9.

39.

Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS.

Taskesen E, Mishra A, van der Sluis S, Ferrari R; International FTD-Genomics Consortium, Veldink JH, van Es MA, Smit AB, Posthuma D, Pijnenburg Y.

Sci Rep. 2018 May 14;8(1):7789. doi: 10.1038/s41598-018-21308-x.

40.

Monitoring the past and choosing the future: the prefrontal cortical influences on voluntary action.

Phillips HN, Cope TE, Hughes LE, Zhang J, Rowe JB.

Sci Rep. 2018 May 8;8(1):7247. doi: 10.1038/s41598-018-25127-y.

41.

The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study.

Devenney E, Swinn T, Mioshi E, Hornberger M, Dawson KE, Mead S, Rowe JB, Hodges JR.

BMC Neurol. 2018 Apr 28;18(1):56. doi: 10.1186/s12883-018-1060-1.

42.

[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.

Passamonti L, Rodríguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D, Jones PS, Arnold R, Borchert RJ, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Neurology. 2018 May 29;90(22):e1989-e1996. doi: 10.1212/WNL.0000000000005610. Epub 2018 Apr 27.

43.

Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study.

Minett T, Su L, Mak E, Williams G, Firbank M, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn D, O'Brien JT.

J Neurol. 2018 Jul;265(7):1528-1539. doi: 10.1007/s00415-018-8873-0. Epub 2018 Apr 25.

PMID:
29696499
44.

CXCR4 involvement in neurodegenerative diseases.

Bonham LW, Karch CM, Fan CC, Tan C, Geier EG, Wang Y, Wen N, Broce IJ, Li Y, Barkovich MJ, Ferrari R, Hardy J, Momeni P, Höglinger G, Müller U, Hess CP, Sugrue LP, Dillon WP, Schellenberg GD, Miller BL, Andreassen OA, Dale AM, Barkovich AJ, Yokoyama JS, Desikan RS; International FTD-Genomics Consortium (IFGC); International Parkinson’s Disease Genetics Consortium (IPDGC); International Genomics of Alzheimer’s Project (IGAP).

Transl Psychiatry. 2018 Apr 11;8(1):73. doi: 10.1038/s41398-017-0049-7.

45.

Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study.

Mc Ardle R, Morris R, Hickey A, Del Din S, Koychev I, Gunn RN, Lawson J, Zamboni G, Ridha B, Sahakian BJ, Rowe JB, Thomas A, Zetterberg H, MacKay C, Lovestone S, Rochesteron L; Deep and Frequent Phenotyping study team (.

J Alzheimers Dis. 2018;63(1):331-341. doi: 10.3233/JAD-171116. Erratum in: J Alzheimers Dis. 2018;63(4):1557.

PMID:
29614664
46.

White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes.

Lansdall CJ, Coyle-Gilchrist ITS, Jones PS, Vázquez Rodríguez P, Wilcox A, Wehmann E, Dick KM, Robbins TW, Rowe JB.

Neurology. 2018 Mar 20;90(12):e1066-e1076. doi: 10.1212/WNL.0000000000005175. Epub 2018 Feb 16.

47.

Finger strength, individuation, and their interaction: Relationship to hand function and corticospinal tract injury after stroke.

Wolbrecht ET, Rowe JB, Chan V, Ingemanson ML, Cramer SC, Reinkensmeyer DJ.

Clin Neurophysiol. 2018 Apr;129(4):797-808. doi: 10.1016/j.clinph.2018.01.057. Epub 2018 Feb 3.

48.

Neurotransmitter deficits from frontotemporal lobar degeneration.

Murley AG, Rowe JB.

Brain. 2018 May 1;141(5):1263-1285. doi: 10.1093/brain/awx327.

49.

Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, Kouri N, Ross OA, Höglinger GU, Muller U, Hardy J; International FTD-Genomics Consortium, Momeni P, Hess CP, Dillon WP, Miller ZA, Bonham LW, Rabinovici GD, Rosen HJ, Schellenberg GD, Franke A, Karlsen TH, Veldink JH, Ferrari R, Yokoyama JS, Miller BL, Andreassen OA, Dale AM, Desikan RS, Sugrue LP.

PLoS Med. 2018 Jan 9;15(1):e1002487. doi: 10.1371/journal.pmed.1002487. eCollection 2018 Jan. Erratum in: PLoS Med. 2018 Jan 29;15(1):e1002504.

50.

Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.

Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, Passamonti L, Vazquez Rodriguez P, Bevan-Jones WR, O'Brien JT, Rowe JB.

Brain. 2018 Feb 1;141(2):550-567. doi: 10.1093/brain/awx347.

Supplemental Content

Loading ...
Support Center